Company news

Keros Therapeutics, Inc. news in 2025

Keros Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Keros Therapeutics Announces Final Results of Tender Offer

November 19, 2025

Keros Therapeutics Announces Preliminary Results of Tender Offer

November 18, 2025

Keros Therapeutics Reports Third Quarter 2025 Financial Results

November 4, 2025

Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

October 19, 2025

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

October 14, 2025

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

September 7, 2025

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

August 27, 2025

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

August 19, 2025

Keros Therapeutics Reports Second Quarter 2025 Financial Results

August 5, 2025

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

August 5, 2025

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

July 16, 2025

Keros Announces Return of $375 Million in Excess Capital to Stockholders

June 8, 2025

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

June 5, 2025

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

May 28, 2025

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees

May 26, 2025

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

May 21, 2025

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value

May 18, 2025

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

May 11, 2025

Keros Reinforces Commitment to Maximizing Stockholder Value

May 7, 2025

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

May 5, 2025

Keros Therapeutics Announces Review of Strategic Alternatives

April 9, 2025

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

March 30, 2025

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

February 25, 2025

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

January 29, 2025

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

January 20, 2025

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

January 14, 2025

Decks in 2025